RT Journal Article SR Electronic T1 Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting β2-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP P3636 VO 42 IS Suppl 57 A1 Karen Mezzi A1 Danny McBryan A1 John Pallante A1 Vijay Alagappan A1 Hungta Chen A1 Donald Banerji YR 2013 UL http://erj.ersjournals.com/content/42/Suppl_57/P3636.abstract AB IntroductionThe ILLUMINATE study evaluated the superiority of the once-daily QVA149 110/50µg, a dual bronchodilator combining the LABA indacaterol and the LAMA glycopyrronium, compared to twice-daily LABA/ICS, salmeterol/fluticasone 50/500µg (SFC), in terms of efficacy, safety and tolerability in patients (pts) with moderate-to-severe COPD. This analysis reports the efficacy and safety of QVA149 vs. SFC in the sub-group population using fixed-dose LABA/ICS prior to study enrollment.Methods122 pts on LABA/ICS prior to study entry were randomized to QVA149 (n=54) and SFC (n=68). FEV1 area under the curve for 0-12h (AUC0-12h), pre-dose trough FEV1, rescue medication use, exacerbations and safety were assessed after 26wks.ResultsQVA149 significantly improved FEV1 AUC0-12h, pre-dose trough FEV1 and reduced rescue medication use in COPD pts regardless of previous LABA/ICS use at study entry (Table). Number of exacerbations (QVA149: 23; SFC: 41) and pts with incidence of adverse events (QVA149: 50%; SFC: 55.9%) was numerically lower with QVA149.View this table:ConclusionIn the subpopulation previously treated with LABA/ICS, QVA149 demonstrated significant improvements in lung function and rescue therapy use compared to SFC. These results were consistent with the overall study population.